4 Colistimethate Sodium (nebulized; numerous generic names) 53
Table 12: Product Profile - Colistimethate Sodium 54
An additional problem is that prescribing units differ between manufacturers, including mg for colistin base activity (CBA) and colistimethate sodium
(CMS), and international units for CMS.
NYSE: FRX), an international pharmaceutical manufacturer and marketer, today announced that it has been granted European Medicines Agency (EMA) approval to market Colobreathe dry powder colistimethate sodium for inhalation for treating cystic fibrosis patients aged 6 years and older with chronic lung infection caused by P.
In 2011 Forest Laboratories acquired all rights held by Gruenenthal to colistimethate sodium in several European countries and also reacquired rights to Colobreathe previously licensed from Forest.
Colobreathe is a capsule containing 1,662,500 IU of colistimethate sodium which is approximately equal to 125 mg.
LONDON, September 15 /PRNewswire/ -- Forest Laboratories UK Ltd, (a wholly owned subsidiary of Forest Laboratories Inc) announced that following the successful completion of its pan-European multi-centre phase III study (the Freedom Study), it has applied to the European Medicines Evaluation Agency (EMEA) to licence its new formulation dry powder colistimethate sodium
for inhalation (Colobreathe(R)) for use by Cystic Fibrosis patients.
1Million Iu, Powder For Solution For Injection In 10Ml Vial
Objective: Colistimethate Sodium
(CMS hereinafter) is a rapidly bactericidal antimicrobial agent with a significant post-antibiotic effect against multidrug resistant Gram-negative pathogens.
Framework agreement with a single operator per lot for provision of medicines Ertapenem (DOE), colistimethate sodium
(DOE), Tirofiban (DOE), Cefepime (DOE), imipenem / cilastatin (DOE) and Antiretrovirals in combination lamivudine (DOE) / Zidovudine (DOE).
5% (hydrocortisone cream, USP), ANUSOL-HC 25-mg SUPPOSITORY (hydrocortisone acetate) and COLY-MYCIN(R)-M PARENTERAL (sterile colistimethate sodium
, USP) and certain manufacturing contracts with third parties from Warner-Lambert Company in February 1998, and the sales growth of certain significant branded pharmaceutical products, including in particular the CORTISPORIN(R) product line.